Drugs / Allogeneic CART-NKG2D cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06709469 | Jul 2025 → Jun 2030 expected | precursor lymphoblastic lymphoma/leukemia | Instituto de Investigación Hospital Universitario La Paz | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic CART-NKG2D cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06709469 ↗ |
| Action | Deplete | “T-ALL and acute myeloid leukemia (AML) cell lines were more sensitive to CART-NKG2D (chimeric-antigen receptor Natural-killer group 2, member D) cytotoxicity than B-ALL cell lines.” NCT06709469 ↗ |
| Modality | Cell therapy | “allogeneic CART-NKG2D cells” NCT06709469 ↗ |
| Route | Intravenous | “will be infused; intravenously.” NCT06709469 ↗ |